Clearside Biomedical, Inc. (CLSD)

Clearside Biomedical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	20.02	28.92	48.26	30.44	17.29
Cash & Short-Term Investments	20.02	28.92	48.26	30.44	17.29
Cash Growth	-30.78%	-40.07%	58.56%	76.06%	-23.49%
Receivables	0.51	0.47	-	10	-
Prepaid Expenses	0.73	0.72	0.7	0.92	0.72
Restricted Cash	-	-	0.16	0.1	0.1
Other Current Assets	0.01	0.01	0.28	0.68	0.01
Total Current Assets	21.27	30.12	49.4	42.14	18.12
Property, Plant & Equipment	3.82	3.87	1.87	0.61	0.94
Other Long-Term Assets	0.03	0.03	0.03	0.16	0.26
Total Assets	25.13	34.02	51.3	42.9	19.32
Accounts Payable	1.45	2.21	1.05	0.94	2
Accrued Expenses	2.97	4.17	4.18	3.31	1.58
Current Portion of Long-Term Debt	-	-	-	-	0.99
Current Portion of Leases	0.38	0.36	0.35	0.39	0.37
Current Unearned Revenue	-	0.08	0.21	-	5
Total Current Liabilities	4.79	6.81	5.78	4.64	9.94
Long-Term Debt	51.77	41.99	33.98	-	-
Long-Term Leases	0.33	0.65	0.94	0.29	0.62
Other Long-Term Liabilities	7.09	0.48	-	-	-
Total Liabilities	63.98	49.93	40.7	4.93	10.56
Common Stock	0.08	0.06	0.06	0.06	0.05
Additional Paid-In Capital	316.34	304.95	298.98	293.41	264.58
Retained Earnings	-355.28	-320.92	-288.44	-255.49	-255.87
Total Common Equity	-38.86	-15.91	10.61	37.98	8.76
Shareholders' Equity	-38.86	-15.91	10.61	37.98	8.76
Total Liabilities & Equity	25.13	34.02	51.3	42.9	19.32
Total Debt	52.47	43	35.26	0.68	1.98
Net Cash (Debt)	-32.45	-14.08	13	29.76	15.31
Net Cash Growth	-	-	-56.33%	94.43%	-5.43%
Net Cash Per Share	-0.44	-0.23	0.22	0.50	0.33
Filing Date Shares Outstanding	77.14	74.72	61.36	60.15	57.42
Total Common Shares Outstanding	76.58	62.85	60.64	59.72	51.86
Working Capital	16.48	23.31	43.62	37.5	8.18
Book Value Per Share	-0.51	-0.25	0.17	0.64	0.17
Tangible Book Value	-38.86	-15.91	10.61	37.98	8.76
Tangible Book Value Per Share	-0.51	-0.25	0.17	0.64	0.17
Machinery	2.03	0.85	0.61	0.53	0.53
Construction In Progress	1.87	2.59	0.53	-	-
Leasehold Improvements	0.48	0.48	0.48	0.67	0.67

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q